Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy
Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2019-12, Vol.145 (11), p.3101-3111 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3111 |
---|---|
container_issue | 11 |
container_start_page | 3101 |
container_title | International journal of cancer |
container_volume | 145 |
creator | Demontoux, Lucie Derangère, Valentin Pilot, Thomas Thinselin, Chloé Chevriaux, Angélique Chalmin, Fanny Bouyer, Florence Ghiringhelli, François Rébé, Cédric |
description | Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy.
What's new?
Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy. |
doi_str_mv | 10.1002/ijc.32590 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2265771490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2265771490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi1ERZfCgRdAlriUQ1rbiZP4iFaUFlXqBc6R40xYrxw72E5RHoc3ZZYUDkhcbI__b37N6CfkDWdXnDFxbY_mqhRSsWdkx5lqCia4fE52qLGi4WV9Tl6mdGSMc8mqF-S85GVViVrsyM_bdQ45eGtoyhFSouAP2htI1AQXPDWnIlIDztEBdD5Q64fFwED7lc5OZ-uXCZVoH_H9iH3aD9RO0-Kx_5s12rkV6zmGTcw2L1OIFMYRRbPSMKJljnpGD5wEtKPmAFPIB8DP9RU5G7VL8PrpviBfbz5-2d8W9w-f7vYf7gtTti0rZFmjI-9bqSuu6lYakMOoetOqtudjL6qK9_2gKtk3RgrgCiQMslGNqpXUTXlBLjdfnPT7Ail3k02ntbWHsKROiFo2Da8UQ_TdP-gxLNHjdJ0oWSmbCg-k3m-UiSGlCGM3RzvpuHacdafcOsyt-50bsm-fHJd-guEv-ScoBK434Id1sP7fqbv7vN8sfwHIQKXf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2303574035</pqid></control><display><type>article</type><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</creator><creatorcontrib>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</creatorcontrib><description>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy.
What's new?
Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.32590</identifier><identifier>PMID: 31344262</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animals ; Antitumor activity ; Apoptosis ; Cancer ; Carboplatin ; Caspase ; CD8 antigen ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - metabolism ; Cell activation ; Cell death ; Cell Line, Tumor ; Cell Survival - drug effects ; Cell viability ; Chemotherapy ; Cisplatin ; Colon cancer ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - immunology ; Colorectal cancer ; Colorectal carcinoma ; Female ; Gastric cancer ; HCT116 Cells ; HT29 Cells ; Humans ; hypotonic stress ; Immunodeficiency ; immunogenic cell death ; Immunogenicity ; Injections, Intraperitoneal ; Lymphocyte Activation - drug effects ; Lymphocytes ; Lymphocytes T ; Medical prognosis ; Medical research ; Metastases ; Mice ; Nodules ; Oligomerization ; Organs ; Osmolarity ; Osmotic Pressure ; Oxaliplatin ; Oxaliplatin - administration & dosage ; Oxaliplatin - pharmacology ; peritoneal carcinomatosis ; Peritoneal Neoplasms - drug therapy ; Peritoneal Neoplasms - immunology ; Peritoneal Neoplasms - secondary ; Peritoneum ; Platinum ; platinum derivatives ; Surgery ; Xenograft Model Antitumor Assays</subject><ispartof>International journal of cancer, 2019-12, Vol.145 (11), p.3101-3111</ispartof><rights>2019 UICC</rights><rights>2019 UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</citedby><cites>FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</cites><orcidid>0000-0002-5465-8305 ; 0000-0001-8831-145X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.32590$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.32590$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31344262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Demontoux, Lucie</creatorcontrib><creatorcontrib>Derangère, Valentin</creatorcontrib><creatorcontrib>Pilot, Thomas</creatorcontrib><creatorcontrib>Thinselin, Chloé</creatorcontrib><creatorcontrib>Chevriaux, Angélique</creatorcontrib><creatorcontrib>Chalmin, Fanny</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Rébé, Cédric</creatorcontrib><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy.
What's new?
Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</description><subject>Animals</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Carboplatin</subject><subject>Caspase</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell activation</subject><subject>Cell death</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Cell viability</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - immunology</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Female</subject><subject>Gastric cancer</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>hypotonic stress</subject><subject>Immunodeficiency</subject><subject>immunogenic cell death</subject><subject>Immunogenicity</subject><subject>Injections, Intraperitoneal</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Mice</subject><subject>Nodules</subject><subject>Oligomerization</subject><subject>Organs</subject><subject>Osmolarity</subject><subject>Osmotic Pressure</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Oxaliplatin - pharmacology</subject><subject>peritoneal carcinomatosis</subject><subject>Peritoneal Neoplasms - drug therapy</subject><subject>Peritoneal Neoplasms - immunology</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Peritoneum</subject><subject>Platinum</subject><subject>platinum derivatives</subject><subject>Surgery</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAQhi1ERZfCgRdAlriUQ1rbiZP4iFaUFlXqBc6R40xYrxw72E5RHoc3ZZYUDkhcbI__b37N6CfkDWdXnDFxbY_mqhRSsWdkx5lqCia4fE52qLGi4WV9Tl6mdGSMc8mqF-S85GVViVrsyM_bdQ45eGtoyhFSouAP2htI1AQXPDWnIlIDztEBdD5Q64fFwED7lc5OZ-uXCZVoH_H9iH3aD9RO0-Kx_5s12rkV6zmGTcw2L1OIFMYRRbPSMKJljnpGD5wEtKPmAFPIB8DP9RU5G7VL8PrpviBfbz5-2d8W9w-f7vYf7gtTti0rZFmjI-9bqSuu6lYakMOoetOqtudjL6qK9_2gKtk3RgrgCiQMslGNqpXUTXlBLjdfnPT7Ail3k02ntbWHsKROiFo2Da8UQ_TdP-gxLNHjdJ0oWSmbCg-k3m-UiSGlCGM3RzvpuHacdafcOsyt-50bsm-fHJd-guEv-ScoBK434Id1sP7fqbv7vN8sfwHIQKXf</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Demontoux, Lucie</creator><creator>Derangère, Valentin</creator><creator>Pilot, Thomas</creator><creator>Thinselin, Chloé</creator><creator>Chevriaux, Angélique</creator><creator>Chalmin, Fanny</creator><creator>Bouyer, Florence</creator><creator>Ghiringhelli, François</creator><creator>Rébé, Cédric</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5465-8305</orcidid><orcidid>https://orcid.org/0000-0001-8831-145X</orcidid></search><sort><creationdate>20191201</creationdate><title>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</title><author>Demontoux, Lucie ; Derangère, Valentin ; Pilot, Thomas ; Thinselin, Chloé ; Chevriaux, Angélique ; Chalmin, Fanny ; Bouyer, Florence ; Ghiringhelli, François ; Rébé, Cédric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-536eff1b85a419685ce5df9bc898b1fb2441bbd945b7c52e19e5ed57979695a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Carboplatin</topic><topic>Caspase</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell activation</topic><topic>Cell death</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Cell viability</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - immunology</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Female</topic><topic>Gastric cancer</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>hypotonic stress</topic><topic>Immunodeficiency</topic><topic>immunogenic cell death</topic><topic>Immunogenicity</topic><topic>Injections, Intraperitoneal</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Mice</topic><topic>Nodules</topic><topic>Oligomerization</topic><topic>Organs</topic><topic>Osmolarity</topic><topic>Osmotic Pressure</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Oxaliplatin - pharmacology</topic><topic>peritoneal carcinomatosis</topic><topic>Peritoneal Neoplasms - drug therapy</topic><topic>Peritoneal Neoplasms - immunology</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Peritoneum</topic><topic>Platinum</topic><topic>platinum derivatives</topic><topic>Surgery</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Demontoux, Lucie</creatorcontrib><creatorcontrib>Derangère, Valentin</creatorcontrib><creatorcontrib>Pilot, Thomas</creatorcontrib><creatorcontrib>Thinselin, Chloé</creatorcontrib><creatorcontrib>Chevriaux, Angélique</creatorcontrib><creatorcontrib>Chalmin, Fanny</creatorcontrib><creatorcontrib>Bouyer, Florence</creatorcontrib><creatorcontrib>Ghiringhelli, François</creatorcontrib><creatorcontrib>Rébé, Cédric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Demontoux, Lucie</au><au>Derangère, Valentin</au><au>Pilot, Thomas</au><au>Thinselin, Chloé</au><au>Chevriaux, Angélique</au><au>Chalmin, Fanny</au><au>Bouyer, Florence</au><au>Ghiringhelli, François</au><au>Rébé, Cédric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>145</volume><issue>11</issue><spage>3101</spage><epage>3111</epage><pages>3101-3111</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Colorectal cancer is a highly metastatic disease that could invade various distal organs and also the peritoneal cavity leading to peritoneal carcinomatosis. This is a terminal condition with poor prognosis and only palliative treatments such as cytoreductive surgery and intraperitoneal chemotherapy are proposed to some patients. However, clinicians use different parameters of treatments without any consensus. Here we decided to evaluate the effect of osmolarity in the efficacy of this procedure to kill colon cancer cells. We first show that a short exposure of platinum derivatives in hypotonic conditions is more efficient to decrease cell viability of human and murine colon cancer cells in vitro as compared to isotonic conditions. This is related to more important incorporation of platinum and the capacity of hypotonic stress to induce the copper transporter CTR1 oligomerization. Oxaliplatin in hypotonic conditions induces caspase‐dependent cell death of colon cancer cells. Moreover, hypotonic conditions also modulate the capacity of oxaliplatin and cisplatin (but not carboplatin) to induce immunogenic cell death (ICD). In vivo, oxaliplatin in hypotonic conditions increases CD8+ T cell tumor infiltration and activation. Finally, in a murine peritoneal carcinomatosis model, oxaliplatin in hypotonic conditions is the only tested protocol which is able to slow down the appearance of tumor nodules and increase mice survival, while showing no effect in CD8+ T cells depleted mice or in immunodeficient mice. Altogether, our study provides new information both in vitro and in a preclinical model of peritoneal carcinomatosis, which highlights the importance of hypoosmolarity in intraperitoneal chemotherapy.
What's new?
Colorectal cancer can lead to peritoneal carcinomatosis, a terminal condition with only palliative treatments such as intraperitoneal chemotherapy currently available. To date, no consensus on treatment parameters exists. Here, hypotonic stress improves platinum derivatives‐induced cell death in human and murine colon cancer cell lines. A short exposition of cancer cells to oxaliplatin in hypotonic conditions was sufficient to induce immunogenic cell death. In a peritoneal carcinomatosis model, hypotonic conditions induced mice survival in a CD8+ T cell‐dependent manner. The findings suggest that oxaliplatin in hypotonic conditions, in the absence of hyperthermia, should be considered by surgeons practicing intraperitoneal chemotherapy.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31344262</pmid><doi>10.1002/ijc.32590</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5465-8305</orcidid><orcidid>https://orcid.org/0000-0001-8831-145X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-7136 |
ispartof | International journal of cancer, 2019-12, Vol.145 (11), p.3101-3111 |
issn | 0020-7136 1097-0215 |
language | eng |
recordid | cdi_proquest_miscellaneous_2265771490 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Animals Antitumor activity Apoptosis Cancer Carboplatin Caspase CD8 antigen CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - metabolism Cell activation Cell death Cell Line, Tumor Cell Survival - drug effects Cell viability Chemotherapy Cisplatin Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - immunology Colorectal cancer Colorectal carcinoma Female Gastric cancer HCT116 Cells HT29 Cells Humans hypotonic stress Immunodeficiency immunogenic cell death Immunogenicity Injections, Intraperitoneal Lymphocyte Activation - drug effects Lymphocytes Lymphocytes T Medical prognosis Medical research Metastases Mice Nodules Oligomerization Organs Osmolarity Osmotic Pressure Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - pharmacology peritoneal carcinomatosis Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - immunology Peritoneal Neoplasms - secondary Peritoneum Platinum platinum derivatives Surgery Xenograft Model Antitumor Assays |
title | Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T11%3A47%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypotonic%20stress%20enhances%20colon%20cancer%20cell%20death%20induced%20by%20platinum%20derivatives%20and%20immunologically%20improves%20antitumor%20efficacy%20of%20intraperitoneal%20chemotherapy&rft.jtitle=International%20journal%20of%20cancer&rft.au=Demontoux,%20Lucie&rft.date=2019-12-01&rft.volume=145&rft.issue=11&rft.spage=3101&rft.epage=3111&rft.pages=3101-3111&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.32590&rft_dat=%3Cproquest_cross%3E2265771490%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2303574035&rft_id=info:pmid/31344262&rfr_iscdi=true |